{"success":true,"data":{"pressRelease":{"id":"165768","rtpr_id":"nGNX3n6GDG-20261009","ticker":"LBRX","exchange":"NASDAQ","all_tickers":["LBRX"],"title":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-10-09T20:42:36.087Z","article_body":"NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB\nPharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines\ncompany dedicated to developing and commercializing high-impact therapies that\naddress the multiple dimensions of underserved brain disorders, today\nannounced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical\nOfficer and Joseph Miller, the new Chief Financial Officer of LB\nPharmaceuticals, equity awards outside of, but subject to the terms and\nconditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The\nequity awards were granted on October 9, 2026, pursuant to the “inducement\ngrant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an\ninducement material to Dr. Kozauer and Mr. Miller entering into employment\nwith LB Pharmaceuticals.\n\nDr. Kozauer and Mr. Miller each received an option to purchase 200,000 shares\nof LB Pharmaceuticals’ common stock. The options carry a ten-year term and\nan exercise price per share equal to $37.22, which was the closing price of LB\nPharmaceuticals’ common stock on the date of grant, and vests over 4 years,\nwith 25% of the shares underlying the options vesting on the first anniversary\nof the grant date and an additional 1/48th of the shares vesting monthly\nthereafter, subject to continuous service through the applicable vesting\ndates.\n\nAbout LB Pharmaceuticals\n\nLB Pharmaceuticals is a neuromedicines company dedicated to developing and\ncommercializing high-impact therapies that address the multiple dimensions of\nunderserved brain disorders. The Company is building a pipeline that leverages\nthe broad therapeutic potential of its lead product candidate, LB-102, which\nthe Company believes has the opportunity to be the first benzamide\nantipsychotic drug approved for neuropsychiatric disorders in the United\nStates. LB-102, if approved, has the potential to become a mainstay of\npsychiatric practice by offering a balanced clinical activity and tolerability\nprofile that provides a potentially attractive alternative to branded and\ngeneric therapeutics for the treatment of a broad range of neuropsychiatric\ndiseases.\n\nMedia and Investor Contact: \n\nEllen Rose\nerose@lbpharma.us\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/90903161-520e-409f-b2ac-dd18677b4bb8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3n6GDG-20261009","title":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"LBRX","created":"2026-10-09T20:42:36.087Z","tickers":["LBRX"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB\nPharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines\ncompany dedicated to developing and commercializing high-impact therapies that\naddress the multiple dimensions of underserved brain disorders, today\nannounced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical\nOfficer and Joseph Miller, the new Chief Financial Officer of LB\nPharmaceuticals, equity awards outside of, but subject to the terms and\nconditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The\nequity awards were granted on October 9, 2026, pursuant to the “inducement\ngrant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an\ninducement material to Dr. Kozauer and Mr. Miller entering into employment\nwith LB Pharmaceuticals.\n\nDr. Kozauer and Mr. Miller each received an option to purchase 200,000 shares\nof LB Pharmaceuticals’ common stock. The options carry a ten-year term and\nan exercise price per share equal to $37.22, which was the closing price of LB\nPharmaceuticals’ common stock on the date of grant, and vests over 4 years,\nwith 25% of the shares underlying the options vesting on the first anniversary\nof the grant date and an additional 1/48th of the shares vesting monthly\nthereafter, subject to continuous service through the applicable vesting\ndates.\n\nAbout LB Pharmaceuticals\n\nLB Pharmaceuticals is a neuromedicines company dedicated to developing and\ncommercializing high-impact therapies that address the multiple dimensions of\nunderserved brain disorders. The Company is building a pipeline that leverages\nthe broad therapeutic potential of its lead product candidate, LB-102, which\nthe Company believes has the opportunity to be the first benzamide\nantipsychotic drug approved for neuropsychiatric disorders in the United\nStates. LB-102, if approved, has the potential to become a mainstay of\npsychiatric practice by offering a balanced clinical activity and tolerability\nprofile that provides a potentially attractive alternative to branded and\ngeneric therapeutics for the treatment of a broad range of neuropsychiatric\ndiseases.\n\nMedia and Investor Contact: \n\nEllen Rose\nerose@lbpharma.us\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/90903161-520e-409f-b2ac-dd18677b4bb8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-09T20:42:36.127355063Z","server_sent_at_ms":1791578556127},"received_at":"2026-10-09T20:42:36.179Z","source_url":null},"analysis":{"id":"154154","press_release_id":"165768","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"LB Pharmaceuticals granted inducement equity awards to new Chief Medical Officer Dr. Susan G. Kozauer and new CFO Joseph Miller under Nasdaq Listing Rule 5635(c)(4).\n\nEach executive received a ten-year option to purchase 200,000 shares at $37.22, vesting over four years with a 25% cliff at the first anniversary.\n\nThe grants confirm the hiring of the two new C-suite officers but carry no new clinical or financial news; the company's lead asset remains LB-102.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement-grant filing tied to new CMO/CFO hires -- suppress or note only for executive-tracking agents."},"keyFigures":{"customDimensions":{"vesting_years":4,"exercise_price":37.22,"options_per_exec":200000}},"namedEntities":{"people":[{"name":"Dr. Susan G. Kozauer","role":"Chief Medical Officer"},{"name":"Joseph Miller","role":"Chief Financial Officer"},{"name":"Ellen Rose","role":"Media and Investor Contact"}],"products":["LB-102"],"companies":[{"name":"LB Pharmaceuticals Inc","ticker":"LBRX","relationship":"filer"}],"dollarAmounts":[{"amount":"$37.22","context":"option exercise price, equal to closing price on grant date"}]},"materialImpact":{"score":1,"reasoning":"Routine disclosure of Nasdaq-rule inducement equity grants to a new CMO and CFO. No new clinical, financial, or strategic information."},"tickerRelevance":{"others":[],"primary":"LBRX"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":["executive_change"],"importanceComponents":{"tickerTier":"micro-cap-biotech","eventGravity":"boilerplate-equity-grant","executiveHires":true}},"event_type":"board_change","event_type_secondary":["executive_change"],"sentiment":"neutral","material_impact_score":1,"narrative":"LB Pharmaceuticals granted inducement equity awards to new Chief Medical Officer Dr. Susan G. Kozauer and new CFO Joseph Miller under Nasdaq Listing Rule 5635(c)(4).\n\nEach executive received a ten-year option to purchase 200,000 shares at $37.22, vesting over four years with a 25% cliff at the first anniversary.\n\nThe grants confirm the hiring of the two new C-suite officers but carry no new clinical or financial news; the company's lead asset remains LB-102.","key_figures":{"customDimensions":{"vesting_years":4,"exercise_price":37.22,"options_per_exec":200000}},"named_entities":{"people":[{"name":"Dr. Susan G. Kozauer","role":"Chief Medical Officer"},{"name":"Joseph Miller","role":"Chief Financial Officer"},{"name":"Ellen Rose","role":"Media and Investor Contact"}],"products":["LB-102"],"companies":[{"name":"LB Pharmaceuticals Inc","ticker":"LBRX","relationship":"filer"}],"dollarAmounts":[{"amount":"$37.22","context":"option exercise price, equal to closing price on grant date"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T20:42:39.834Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap-biotech","eventGravity":"boilerplate-equity-grant","executiveHires":true}},"durationMs":3640,"modelName":"glm-5.3-flashx"}}